UK BIOCENTRE LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-05-17.

• ◆

  6 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -27.8%

  £21,160,008 → £15,276,422

• Cash

  -20.6%

  £6,308,374 → £5,010,773

• Net assets

  -3.5%

  £8,287,754 → £7,999,916

• Employees

  -18.2%

  181 → 148

• Operating profit

  -129.8%

  £1,902,917 → -£566,162

• Profit before tax

  -113.7%

  £2,156,888 → -£295,473

• Wages

  -17%

  £6,205,198 → £5,151,218

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

James Cowper Kreston Audit

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“With net assets of £7,999,916 on 30 September 2025, the financial statements have been prepared on a going concern basis, which the Directors consider to be appropriate for the following reasons. The Directors have undertaken a comprehensive review of the Company's financial position and cash flow forecasts, extending beyond 12 months from the date of approval of these financial statements. These forecasts incorporate assumptions about reasonably possible downside scenarios, including potential fluctuations in processing income and their corresponding impact on cash flow. Through this analysis, the Directors have concluded that the Company will have sufficient financial resources to meet its operational needs and liabilities as they fall due over the going concern period.”

Significant events

• “On 1 October 2025 a Transfer Event occurred in respect of the 1 A Ordinary Share in UK Biocentre Limited held by UK Biobank Limited. In accordance with the Company's Articles of Association, that share was subsequently compulsorily transferred to UK Biocentre Limited for nil consideration on 10 October 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

6

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.